Why We Invested in Generation Lab: Revolutionizing Biological Age Measurement
Most people, along with their healthcare providers, currently lack reliable tools to accurately understand how quickly their bodies are aging. By the time traditional medical tests detect a problem, significant damage has often already occurred. Generation Lab is addressing this critical gap with its innovative approach. The company’s flagship diagnostic platform, SystemAge™, is the fastest-growing longevity platform in the world. It measures biological aging across 19 different organ systems using intact primary blood data, without relying on arbitrary transformations or approximations.
Unlike other methods that produce a single, often inconsistent “biological age” number, SystemAge™ delivers a detailed report at the organ level. This report includes personalized insights that help both clinicians and consumers track the impact of therapies, lifestyle changes, or preventative measures in a clear and measurable way. By detecting biological changes at the molecular level, SystemAge™ enables true preventive medicine. It spots early signs of dysfunction long before symptoms appear, empowering individuals to slow or even reverse aging and prevent disease progression before it takes hold.
SystemAge™: A Breakthrough in Longevity Diagnostics
Since its launch less than a year ago, Generation Lab has achieved remarkable commercial success. The company has signed agreements with over 275 clinics worldwide, including leading longevity physicians and wellness centers. SystemAge™ has already generated more than 300 million human-aging data points, supporting a diagnostic accuracy rate of 99.9%. This rapid adoption makes SystemAge™ the most widely used longevity diagnostic platform on the market.
The technology behind SystemAge™ is backed by extensive clinical validation. Studies have shown measurable reversals in biological age, including a 13.6-year improvement in brain function and a 4.9-year improvement in reproductive system health following targeted interventions. This scientific rigor is rooted in the work of co-founder Professor Irina Conboy of UC Berkeley, a world leader in aging and regenerative biology. Her groundbreaking discovery of the non-linear physiological curve of DNA methylation aging forms the foundation of the SystemAge™ model.
Generation Lab’s leadership team also includes CEO and co-founder Alina Su, a Harvard Medical School PhD candidate in Biological and Biomedical Science and a serial biotech entrepreneur. COO Michael Suswal brings valuable experience from co-founding Standard AI, a company that raised over $250 million and achieved a valuation exceeding $1 billion.
Why We Invested in Generation Lab: Building the Future of Preventive Healthcare
The field of consumer longevity is entering a new phase, fueled by public figures and investors, with global funding surpassing $8.4 billion in 2024. However, until now, measurement tools have not kept pace with this growth. SystemAge™ fills this critical gap by offering the precision and scalability needed to integrate longevity diagnostics into mainstream preventive healthcare.
At Samsung Next, we seek founders who are building the infrastructure of the future. Generation Lab stands out for its scientific rigor, market readiness, and strategic potential. The company’s technology is built on decades of validated academic research and hundreds of millions of real-world data points. It has rapidly gained adoption across both clinical and consumer longevity markets.
Moreover, Generation Lab presents opportunities to integrate epigenetic diagnostics with Samsung’s consumer health ecosystem. This integration could combine wearable technology and biomarker data to provide continuous, personalized health tracking. Generation Lab’s long-term vision is to develop an AI-powered, closed-loop longevity platform that enables people not only to measure but also to meaningfully reverse biological aging.
As longevity moves from a niche interest to a clinical standard, we believe Generation Lab is poised to become the trusted authority in aging measurement and optimization. That is why we are proud to support Generation Lab as part of its $11 million seed funding round led by Accel, alongside notable investors such as Steve Aoki, Giannis Antetokounmpo, and Simu Liu.
Diane Choi is an investor at Samsung Next. Samsung Next’s investment strategy reflects its own views and does not represent the vision or strategy of any other Samsung business unit, including Samsung Electronics.
For more stories on this topic, visit our category page.
Source: original article.